Lannett Company's - LCI market analysis on 19th January 2021

Transaction Date	Recipient	Shares	Type	Price	Value
2nd January 2021	Timothy C Crew	1,905	Payment by withholding	$6.52	$12,420.60
26th October 2020	John Kozlowski	658	Payment by withholding	$6.78	$4,461.24
22nd September 2020	John Kozlowski	87	Payment by withholding	$6.08	$528.96
7th September 2020	John Abt	10,000	Grant/award etc.	$0.00
7th September 2020	John Kozlowski	5,000	Grant/award etc.	$0.00
3rd September 2020	John Abt	1,000	Open or private sale	$5.27	$5,270.00
1st September 2020	Timothy C Crew	3,000	Open or private purchase	$5.10	$15,300.00
1st September 2020	Patrick G Lepore	38,986	Grant/award etc.	$0.00
1st September 2020	Melissa Rewolinski	38,986	Grant/award etc.	$0.00
1st September 2020	Paul Taveira	38,986	Grant/award etc.	$0.00

Lannett Company

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 4/10.

Lannett Co., Inc. engages in the development, manufacture, marketing, and distribution of generic pharmaceutical products. It offers products in different forms including capsules, tablets, liquids, powders, and sprays. The company was founded in 1942 and is headquartered in Philadelphia, PA.

Ticker: LCI

Sector: Healthcare

Industry: Drug Manufacturers—Specialty & Generic

SEC Central Index Key (CIK): 57725

Employees: 1020

Exchange: New York Stock Exchange

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis